These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8061425)

  • 1. Phase I clinical evaluation of a new iron oxide MR contrast agent.
    McLachlan SJ; Morris MR; Lucas MA; Fisco RA; Eakins MN; Fowler DR; Scheetz RB; Olukotun AY
    J Magn Reson Imaging; 1994; 4(3):301-7. PubMed ID: 8061425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study.
    Hudgins PA; Anzai Y; Morris MR; Lucas MA
    AJNR Am J Neuroradiol; 2002 Apr; 23(4):649-56. PubMed ID: 11950660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran-10: phase II clinical trial data.
    Sharma R; Saini S; Ros PR; Hahn PF; Small WC; de Lange EE; Stillman AE; Edelman RR; Runge VM; Outwater EK; Morris M; Lucas M
    J Magn Reson Imaging; 1999 Feb; 9(2):291-4. PubMed ID: 10077027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide.
    Hamm B; Staks T; Taupitz M; Maibauer R; Speidel A; Huppertz A; Frenzel T; Lawaczeck R; Wolf KJ; Lange L
    J Magn Reson Imaging; 1994; 4(5):659-68. PubMed ID: 7981510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dextran-coated superparamagnetic iron oxide, an MR contrast agent for assessing lymph nodes in the head and neck.
    Anzai Y; McLachlan S; Morris M; Saxton R; Lufkin RB
    AJNR Am J Neuroradiol; 1994 Jan; 15(1):87-94. PubMed ID: 7511324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MR imaging with i.v. superparamagnetic iron oxide: efficacy in the detection of focal hepatic lesions.
    Winter TC; Freeny PC; Nghiem HV; Mack LA; Patten RM; Thomas CR; Elliott S
    AJR Am J Roentgenol; 1993 Dec; 161(6):1191-8. PubMed ID: 8249724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation.
    Harisinghani MG; Saini S; Weissleder R; Hahn PF; Yantiss RK; Tempany C; Wood BJ; Mueller PR
    AJR Am J Roentgenol; 1999 May; 172(5):1347-51. PubMed ID: 10227514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227).
    Saini S; Edelman RR; Sharma P; Li W; Mayo-Smith W; Slater GJ; Eisenberg PJ; Hahn PF
    AJR Am J Roentgenol; 1995 May; 164(5):1147-52. PubMed ID: 7717222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superparamagnetic iron oxide hepatic MR imaging: efficacy and safety using conventional and fast spin-echo pulse sequences.
    Schwartz LH; Seltzer SE; Tempany CM; Silverman SG; Piwnica-Worms DR; Adams DF; Herman L; Herman LA; Hooshmand R
    J Magn Reson Imaging; 1995; 5(5):566-70. PubMed ID: 8574043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interstitial MR lymphography with iron oxide particles: results in tumor-free and VX2 tumor-bearing rabbits.
    Taupitz M; Wagner S; Hamm B; Binder A; Pfefferer D
    AJR Am J Roentgenol; 1993 Jul; 161(1):193-200. PubMed ID: 8517301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles--initial clinical experience.
    Bellin MF; Roy C; Kinkel K; Thoumas D; Zaim S; Vanel D; Tuchmann C; Richard F; Jacqmin D; Delcourt A; Challier E; Lebret T; Cluzel P
    Radiology; 1998 Jun; 207(3):799-808. PubMed ID: 9609907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging of macrophages in soft-tissue infection in rats: relationship between ultrasmall superparamagnetic iron oxide dose and MR signal characteristics.
    Lutz AM; Weishaupt D; Persohn E; Goepfert K; Froehlich J; Sasse B; Gottschalk J; Marincek B; Kaim AH
    Radiology; 2005 Mar; 234(3):765-75. PubMed ID: 15665219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications.
    Reimer P; Balzer T
    Eur Radiol; 2003 Jun; 13(6):1266-76. PubMed ID: 12764641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient.
    Vogl TJ; Hammerstingl R; Schwarz W; Kümmel S; Müller PK; Balzer T; Lauten MJ; Balzer JO; Mack MG; Schimpfky C; Schrem H; Bechstein WO; Neuhaus P; Felix R
    Invest Radiol; 1996 Nov; 31(11):696-708. PubMed ID: 8915751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical evaluation of citrate-coated monocrystalline very small superparamagnetic iron oxide particles as a new contrast medium for magnetic resonance imaging.
    Taupitz M; Wagner S; Schnorr J; Kravec I; Pilgrimm H; Bergmann-Fritsch H; Hamm B
    Invest Radiol; 2004 Jul; 39(7):394-405. PubMed ID: 15194910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MR imaging of the liver and spleen: a comparison of the effects on signal intensity of two superparamagnetic iron oxide agents.
    Chen F; Ward J; Robinson PJ
    Magn Reson Imaging; 1999 May; 17(4):549-56. PubMed ID: 10231181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions.
    Ros PR; Freeny PC; Harms SE; Seltzer SE; Davis PL; Chan TW; Stillman AE; Muroff LR; Runge VM; Nissenbaum MA
    Radiology; 1995 Aug; 196(2):481-8. PubMed ID: 7617864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver MR imaging with iron oxides: toward consensus and clinical practice.
    Weissleder R
    Radiology; 1994 Dec; 193(3):593-5. PubMed ID: 7972790
    [No Abstract]   [Full Text] [Related]  

  • 19. Ferrimagnetic susceptibility contrast agents.
    Bach-Gansmo T
    Acta Radiol Suppl; 1993; 387():1-30. PubMed ID: 8390776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodistribution and toxicity of MR imaging contrast media.
    Oksendal AN; Hals PA
    J Magn Reson Imaging; 1993; 3(1):157-65. PubMed ID: 8428083
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.